Biosimilars Expert Duncan Emerton Provides an Exclusive Interview in the Run-Up to His Keynote Address at Biosimilars Europe 2016
SMi is delighted to have Duncan Emerton from FirstWord present at the 7th Annual Biosimilars Europe when it returns to London on 29th-30th September 2016.
London, United Kingdom, August 13, 2016 --(PR.com)-- Duncan Emerton is the Senior Director for Syndicated Insights & Analysis at news and intelligence provider, FirstWord Pharma. His current role is to provide unbiased, expert-led insight and analysis across a range of issues within the pharmaceutical industry, including biosimilars.
Duncan Emerton will be opening SMi Groups 7th Annual Biosimilars Europe event in a keynote address when it returns to London this autumn. His talk will provide progressive outlook into the next decade of Biosimilars and map the next targets for biosimilars development. Strategic insight will be given on not only the European Market, but also the US.
As part of the Biosimilars Interview Series for 2016, SMi group caught up with Duncan to discuss industry developments and the upcoming event.
When asked if we will ever see price matching between branded and biosimilar products he said:
“Cost is a key commercial differentiator, but is not the only attribute upon which your biosimilar product or portfolio will be judged by payers. For some companies there could be a temptation to offer deep discounts immediately in order to make rapid market share gains. This has been seen in Nordic markets. Other companies won't adopt this strategy, choosing to adopt a more 'rationale' pricing strategy.”
On factors which may stall biosimilar uptake in 2016, he commented:
“Generally speaking there are three issues which could slow down adoption to future biosimilar uptake, the first is intellectual property. Companies are protecting their IP very aggressively, and several high profile cases are being fought in the courts of the US and Europe.”
The full interview is available to read in the event download centre at:
www.biosimilars-europe.com/prcom
7th Annual Biosimilars Europe Conference
29th-30th September 2016
Holiday Inn Kensington Forum, London, UK
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.biosimilars-europe.com/prcom or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
About FirstWord:
FirstWord Pharma supplies global news and intelligence to the pharmaceutical industry. The service provides the top industry news stories on a daily basis in a format that is quick and easy to access so that users can always be in-the-know about the latest news and developments in their industry. Visit http://www.firstwordpharma.com
Duncan Emerton will be opening SMi Groups 7th Annual Biosimilars Europe event in a keynote address when it returns to London this autumn. His talk will provide progressive outlook into the next decade of Biosimilars and map the next targets for biosimilars development. Strategic insight will be given on not only the European Market, but also the US.
As part of the Biosimilars Interview Series for 2016, SMi group caught up with Duncan to discuss industry developments and the upcoming event.
When asked if we will ever see price matching between branded and biosimilar products he said:
“Cost is a key commercial differentiator, but is not the only attribute upon which your biosimilar product or portfolio will be judged by payers. For some companies there could be a temptation to offer deep discounts immediately in order to make rapid market share gains. This has been seen in Nordic markets. Other companies won't adopt this strategy, choosing to adopt a more 'rationale' pricing strategy.”
On factors which may stall biosimilar uptake in 2016, he commented:
“Generally speaking there are three issues which could slow down adoption to future biosimilar uptake, the first is intellectual property. Companies are protecting their IP very aggressively, and several high profile cases are being fought in the courts of the US and Europe.”
The full interview is available to read in the event download centre at:
www.biosimilars-europe.com/prcom
7th Annual Biosimilars Europe Conference
29th-30th September 2016
Holiday Inn Kensington Forum, London, UK
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.biosimilars-europe.com/prcom or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
About FirstWord:
FirstWord Pharma supplies global news and intelligence to the pharmaceutical industry. The service provides the top industry news stories on a daily basis in a format that is quick and easy to access so that users can always be in-the-know about the latest news and developments in their industry. Visit http://www.firstwordpharma.com
Contact
SMi Group
Teri Arri
+44 (0) 20 7827 6184
http://www.biosimilars-europe.com/prcom
Teri Arri
+44 (0) 20 7827 6184
http://www.biosimilars-europe.com/prcom
Contact
Categories